Skip to content
RDL Network logo
Figure S1 from Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials — Jarem Edwards (2023) | RDL Network